WO2023118258 - TRIAZOLONE DERIVATIVE SALT AS NEUTROPHIL ELASTASE INHIBITOR
National phase entry:
Publication Number
WO/2023/118258
Publication Date
29.06.2023
International Application No.
PCT/EP2022/087169
International Filing Date
21.12.2022
Title **
[English]
TRIAZOLONE DERIVATIVE SALT AS NEUTROPHIL ELASTASE INHIBITOR
[French]
SEL DÉRIVÉ DE TRIAZOLONE EN TANT QU'INHIBITEUR DE L'ÉLASTASE DU NEUTROPHILE
Applicants **
CHIESI FARMACEUTICI S.P.A.
Via Palermo 26/A
43122 Parma, IT
Inventors
AMARI, Gabriele
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
CAPALDI, Carmelida
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
ARMANI, Elisabetta
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
Priority Data
21217142.5
22.12.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1116 | |
| EPO | Filing, Examination | 4598 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2710 |
Total: 9590 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention generally relates to a novel triazolone derivative salt particularly useful as neutrophil elastase inhibitor and to its use as a medicament. The present invention also relates to pharmaceutical compositions comprising the novel triazolone derivative salt and one or more pharmaceutically acceptable carriers and/or excipients thereof and to their use as medicament.[French]
La présente invention concerne de manière générale un nouveau sel dérivé de triazolone particulièrement utile en tant qu'inhibiteur de l'élastase DU neutrophile et son utilisation en tant que médicament. La présente invention concerne également des compositions pharmaceutiques comprenant le nouveau sel dérivé de triazolone et un ou plusieurs supports et/ou excipients pharmaceutiquement acceptables de celui-ci et leur utilisation en tant que médicament.